Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Xspray Pharma in connection with its listing on Nasdaq Stockholm
Mandate

Vinge advises Xspray Pharma in connection with its listing on Nasdaq Stockholm

April 01, 2020 Capital Markets and Public M&A

Vinge advises Xspray Pharma AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm. The prospectus was published on 23 March 2020 and the trading on Nasdaq Stockholm commenced on 27 March 2020.

Xspray Pharma is a product development company that develops improved and generic versions of marketed drugs, primarily protein kinase inhibitors for the treatment of cancer. Xspray has multiple product candidates in clinical development.

Vinge’s team has primarily consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Joel Magnusson, Maria Schultzberg, Stojan Arnerstål and Henrik Wastenson.

Related

Vinge advises Smart Eye Aktiebolag (publ) on its first SEK 300 million bond issue

 Vinge has advised Smart Eye Aktiebolag (publ) (“Smart Eye”) on the company’s first issue of senior unsecured bonds in an aggregate principal amount of SEK 300 million, under a framework of up to SEK 600 million. Skandinaviska Enskilda Banken AB (publ) acted as sole bookrunner in connection with the bond issue.
December 12, 2025

Vinge advises Nordstjernan in connection with the investment in Circura Group

Vinge has advised Nordstjernan in connection with its investment in newly established Circura Group.
December 12, 2025

Vinge has advised Axcel VI and Currentum in connection with the acquisition of Klarins Rör

 Vinge has advised Axcel VI and the Currentum Group in connection with the acquisition of Klarins Rör i Göteborg AB (“Klarins Rör”).
December 09, 2025